International collaborative ovarian neoplasm trial 1: A randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer

Journal of the National Cancer Institute

Volumn 95, Issue 2, 2003, Pages 125-132

  Colombo, Nicoletta ^a   Guthrie, David ^b   Chiari, Stefania ^c   Parmar, Mahesh ^b   Qian, Wendi ^b   Swart, Ann Marie ^b   Torri, Valter ^d   Williams, Christopher ^e   Lissoni, Andrea ^c   Bonazzi, Cristina ^c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c SAN GERARDO HOSPITAL   (Italy)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e Cochrane Cancer Network ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY CANCER; EPITHELIUM TUMOR; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; STATISTICAL ANALYSIS; SURVIVAL TIME;

EID: 0037440317     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.2.125     Document Type: Article

References (22)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-41.
2. Dent SF, Klaassen D, Pater JL, Zee B, Whitehead M. Second primary malignancies following the treatment of early stage ovarian cancer: update of a study by the National Cancer Institute of Canada. Ann Oncol 2000;11:65-8.
3. Björkholm E, Petterson F, Einborn N, Krebs I, Nilsson B, Tjernberg B. Long-term follow-up and prognostic factors in ovarian carcinoma. Acta Radiol Oncol 1982;21:413-9.
4. Hreshchyshyn MM, Park RC, Blessing JA, Norris HJ, Levy D, Lagasse LD, et al. The role of adjuvant therapy in stage I ovarian cancer. Am J Obstet Gynecol 1980;138:139-45.
5. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy In Ovarian Neoplasm trial. J Natl Cancer Inst 2003;95:113-25.
6. Sigurdsson K, Johnsson JE, Trope C. Carcinoma of the ovary, stages I and II. A prospective randomized study of the effects of postoperative chemotherapy and radiotherapy. Ann Chir Gynaecol 1982;71:321-9.
7. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990;322:1021-7.
8. Bolis G, Colombo N, Pecorelli S, Torri V, Marsoni S, Bonazzi C, et al. Adjuvant treatment for early epithelial ovarian cancer; results of two randomized clinical trials comparing cisplatin to no further treatment or chromic phosphate. Ann Oncol 1995;6:887-93.
9. Sevelda P, Gitsch E, Dittrich C, Haider F, Czwewenka K, Schemper M, et al. Therapeutic and prognostic results of a retrospective multicentre ovarian cancer study of FIGO stages I and II. Geburtshilfe Frauenheilkd 1987;47:179-85.
10. Klaassen D, Shelley W, Starreveld A, Kirk M, Boyes D, Gerulath A, et al. Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report. J Clin Oncol 1988;6:1254-63.
11. Vergote IB, Vergote-De Vos LN, Abeler VM, Aas M, Lindegaard MW, Kjorstad KE, et al. Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 1992;69:741-9.
12. Chiara S, Conte P, Franzone P, Orsatti M, Bruzzone M, Rubagotti A, et al. High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy. Am J Clin Oncol 1994;17:72-6.
13. Fyles AW, Thomas GM, Pintilie M, Ackerman I, Levin W. A randomized study of two doses of abdominopelvic radiation therapy for patients with optimally debulked stage I, II and III ovarian cancer. Int J Radiat Oncol Biol Phys 1998;41:543-9.
14. Tropé C, Kaern J, Hogberg T, Abeler V, Hagen B, Kristensen G, et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol 2000;11:281-8.
15. Krafft W, Morack G, Flach W, Behling H, Schirmer A, Bruckmann D, et al. The therapy of early ovarian cancer T1/T2 MO NO. Arch Geschwulstforsch 1980;50:664-71.
16. The ICON Collaborators. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin and cisplatin) in women with ovarian cancer. Lancet 1998;352:1571-6.
17. Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 1989;96:889-92.
18. Serov SF, Scully RE, Sobin LE. International histological classification of tumors, no 9: histological typing of ovarian tumours. Geneva (Switzerland): World Health Organization; 1973. p. 1-56.
19. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-58.
20. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.
21. Parmar MK, Machin D. Survival analysis: a practical approach. Chichester (U.K.): Wiley; 1995.
22. International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage Ovarian carcinoma. J Natl Cancer Inst 2003;95:105-12.